Absci Corporation - Common Stock (ABSI)
Industrials › Services-Commercial Physical & Biological Research
Price History
Feb 9, 2026 — Aug 16, 2026Investment Snapshot
- P/B of 6.40 — trading above book value
- Piotroski F-Score 4/9 — moderate financial health
- Loss-making — negative ROE of -49.6%
- Revenue declining 21% annually
Absci Corporation - Common Stock (ABSI) is a Industrials company operating in Services-Commercial Physical & Biological Research, listed on the NASDAQ , with a market capitalisation of $1.6 billion . Key value metrics: P/B ratio 6.40, Piotroski F-Score 4 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Absci Corporation - Common Stock — Fundamental Analysis Summary
On financial health, ABSI shows a moderate Piotroski F-Score of 4/9, and negative return on equity of -49.6% (sector average: 6.1%), and minimal leverage with a debt-to-equity ratio of 0.02.
StockPik's composite Value Score for ABSI is 40/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
ABSI shows revenue declining at 21% year-over-year, with earnings declining at 12%.